Back to Atlas
CTransientStandard research/education caution
CMP-0359
Investigational/discontinued
Idoxifene
Endocrine / SERM
Breast cancer/osteoporosis research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SERM
- Primary mechanism
- Iodinated tamoxifen analog ER modulation
- Primary market use
- Oncology / endocrine research
Pharmacology
- Molecular weight (Da)
- 533.5
- Oral bioavailability
- Oral investigational
- Half-life
- Not consistently disclosed
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Historical
- Clinical status
- Investigational/discontinued
- Value-for-money score
- 2 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Limited modern development